FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2284355027> ?p ?o ?g. }

• W2284355027 startingPage "21" @default.
• W2284355027 abstract "For patients with major depressive disorder (MDD), monoamine oxidase inhibitors (MAOIs) have efficacy comparable to that of other antidepressants. However, concerns about side effects--particularly hypertensive crisis--and drug-drug interactions have led clinicians to prescribe MAOIs less often than newer antidepressants. A 1999 survey of 573 Michigan psychiatrists found that 30% had not prescribed an MAOI within the past 3 years, and 12% had never prescribed an MAOI. (1) Although there are challenges to using these agents, we prefer prescribing MAOIs to depressed patients who have not responded to previous antidepressant trials over trying untested antidepressant combinations. Currently, MAOIs are used primarily for patients who have not responded to other antidepressant trials and are considered treatment resistant. Treatment-resistant depression (TRD) typically is defined as nonresponse to [greater than or equal to] 3 adequate antidepressant trials. TRD is a major cause of disability and loss of productivity. These patients tend to do poorly over the long term, with high rates of hospitalization and suicide attempts. Several controlled trials have shown that patients who fail other antidepressants may respond to MAOIs. (2-4) Our knowledge regarding MAOIs has grown considerably. We have learned more about depression subtypes that MAOIs may help. As we learned more about dietary restrictions for patients taking MAOIs, the list of forbidden has decreased. Advances in treating a hypertensive crisis have decreased the need for hospitalization. By educating ourselves and our patients about MAOIs, we can provide another option for treating MDD. [ILLUSTRATION OMITTED] An older antidepressant class MAOIs were introduced approximately 60 years ago. Their potential for treating depression was discovered when a tuberculosis treatment--iproniazid--was found to reduce depressive symptoms. Researchers determined iproniazid's antidepressant effects were the result of blocking removal of the amine group by monoamine oxidase (MAO) from dopamine, norepinephrine, and serotonin. (5) A second MAOI, tranylcypromine, was discovered when it was found to be ineffective for treating decongestion. (6) MAOI use in psychiatric practice has undergone significant changes since these medications were introduced. The discovery of hypertensive crises related to tyramine consumption led to decreased MAOI use, as did the rise of tricyclic antidepressants (TCAs) shortly thereafter. In the 1960s, research compared the relative efficacy of MAOIs to TCAs, and they became second-line antidepressants after the TCAs. In the late 1980s, the introduction of fluoxetine and other selective serotonin reuptake inhibitors (SSRIs) resulted in a significant drop-off in MAOI use. Pharmacologic effects MAO is a class of enzymes that initiate oxidation of extracellular neurotransmitters such as serotonin, norepinephrine, and dopamine. MAOIs can be classified based on their relative affinity to MAO as well as their enzyme selectivity. The first distinguishing characteristic is whether the drug binds to MAO in a reversible or irreversible manner. Currently, all MAOIs that are FDA-approved for treating depression bind irreversibly to MAO. As a result, the body must renew its MAO levels before a patient is no longer at risk for a hypertensive crisis, a process that may take up to 2 weeks. Clinicians must take care to ensure their patients avoid foods that contain tyramine and medications contraindicated with MAOIs during this period. MAOIs also differ from each other in enzyme selectivity. There are 2 subtypes of MAO enzymes--MA[O.sub.A] and MA[O.sub.B]. Generally, the antidepressant activity of MAOIs appears to be directed toward MA[O.sub.A] inhibition. MAOA has been found to be more specific for binding to serotonin and norepinephrine and MA0B to be more specific for phenylethylamine. …" @default.
• W2284355027 created "2016-06-24" @default.
• W2284355027 creator A5027303700 @default.
• W2284355027 creator A5084475956 @default.
• W2284355027 date "2012-12-01" @default.
• W2284355027 modified "2023-09-24" @default.
• W2284355027 title "Forgotten Treatment for Depression: Increased Knowledge of MAOIs Has Made These Agents Worthy of Reconsideration" @default.
• W2284355027 hasPublicationYear "2012" @default.
• W2284355027 type Work @default.
• W2284355027 sameAs 2284355027 @default.
• W2284355027 citedByCount "0" @default.
• W2284355027 crossrefType "journal-article" @default.
• W2284355027 hasAuthorship W2284355027A5027303700 @default.
• W2284355027 hasAuthorship W2284355027A5084475956 @default.
• W2284355027 hasConcept C118552586 @default.
• W2284355027 hasConcept C139719470 @default.
• W2284355027 hasConcept C15744967 @default.
• W2284355027 hasConcept C162324750 @default.
• W2284355027 hasConcept C177713679 @default.
• W2284355027 hasConcept C2776867660 @default.
• W2284355027 hasConcept C2779177272 @default.
• W2284355027 hasConcept C2780051608 @default.
• W2284355027 hasConcept C2780733359 @default.
• W2284355027 hasConcept C558461103 @default.
• W2284355027 hasConcept C71924100 @default.
• W2284355027 hasConceptScore W2284355027C118552586 @default.
• W2284355027 hasConceptScore W2284355027C139719470 @default.
• W2284355027 hasConceptScore W2284355027C15744967 @default.
• W2284355027 hasConceptScore W2284355027C162324750 @default.
• W2284355027 hasConceptScore W2284355027C177713679 @default.
• W2284355027 hasConceptScore W2284355027C2776867660 @default.
• W2284355027 hasConceptScore W2284355027C2779177272 @default.
• W2284355027 hasConceptScore W2284355027C2780051608 @default.
• W2284355027 hasConceptScore W2284355027C2780733359 @default.
• W2284355027 hasConceptScore W2284355027C558461103 @default.
• W2284355027 hasConceptScore W2284355027C71924100 @default.
• W2284355027 hasIssue "12" @default.
• W2284355027 hasLocation W22843550271 @default.
• W2284355027 hasOpenAccess W2284355027 @default.
• W2284355027 hasPrimaryLocation W22843550271 @default.
• W2284355027 hasRelatedWork W107287201 @default.
• W2284355027 hasRelatedWork W1964632497 @default.
• W2284355027 hasRelatedWork W2000709742 @default.
• W2284355027 hasRelatedWork W2027714680 @default.
• W2284355027 hasRelatedWork W203499478 @default.
• W2284355027 hasRelatedWork W2077167943 @default.
• W2284355027 hasRelatedWork W2086486268 @default.
• W2284355027 hasRelatedWork W2092504356 @default.
• W2284355027 hasRelatedWork W2114392292 @default.
• W2284355027 hasRelatedWork W2149689957 @default.
• W2284355027 hasRelatedWork W2182109330 @default.
• W2284355027 hasRelatedWork W2314031407 @default.
• W2284355027 hasRelatedWork W2405047879 @default.
• W2284355027 hasRelatedWork W2417854604 @default.
• W2284355027 hasRelatedWork W2469938013 @default.
• W2284355027 hasRelatedWork W2761454908 @default.
• W2284355027 hasRelatedWork W2886137588 @default.
• W2284355027 hasRelatedWork W3159038357 @default.
• W2284355027 hasRelatedWork W46952784 @default.
• W2284355027 hasRelatedWork W59824934 @default.
• W2284355027 hasVolume "11" @default.
• W2284355027 isParatext "false" @default.
• W2284355027 isRetracted "false" @default.
• W2284355027 magId "2284355027" @default.
• W2284355027 workType "article" @default.